SLC22A6
ENSG00000197901
Target class
Transporter
Chromosome
11
Approved drugs
1
Clinical candidates (approved and in development)
2
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- No
- Target name
- SLC22A6
- Gene name
- Solute carrier family 22 member 6
- Gene symbol
- SLC22A6
- Protein name
- Solute carrier family 22 member 6 (Organic anion transporter 1) (hOAT1) (PAH transporter) (hPAHT) (Renal organic anion transporter 1) (hROAT1)
- ROAT1
- PAHT
- OAT1
- Gene biotype
- Protein coding
- Gene family
- Solute carrier family 22
- Target class
- Transporter
- Target type
- Human gene
- Tissues expressed in
- 11
- Highest tissue expression
- 103.03
- Tissue specificity (Gini)
- 0.941
- Tissue specificity (tau)
- 0.992
- KEGG gene identifiers
- hsa:9356
- Reactome pathways
- R-HSA-561048
- Protein interaction confidence
- 0.747308
- Protein interaction partners
- 13
- End position
- 62984967
- Start position
- 62936385
- Chromosome
- 11
- Strand
- Reverse
- Basolateral cell membrane
- Multi-pass membrane protein . Basal cell membrane
- Multi-pass membrane protein . Note=Localized to the basolateral membrane of renal proximal tubular cells (PubMed:9887087). Localized to the basal membrane of Sertoli cells (PubMed:35307651). .
- PubMed 9887087
- PubMed 35307651
- Tissue specificity (tau)
- 0.99177
- Expression inequality (Gini)
- 0.941493
Expression in transcripts per million
- Kidney - Cortex
- 103.03
- Kidney - Medulla
- 21.43
- Brain - Substantia nigra
- 4.48
- Brain - Hypothalamus
- 3.43
- Brain - Nucleus accumbens (basal ganglia)
- 2.73
Expression in transcripts per million
- Kidney - Cortex103.03
- Kidney - Medulla21.43
- Brain - Substantia nigra4.48
- Brain - Hypothalamus3.43
- Brain - Nucleus accumbens (basal ganglia)2.73
- Brain - Caudate (basal ganglia)2.59
- Brain - Putamen (basal ganglia)1.72
- Brain - Spinal cord (cervical c-1)1.57
- Brain - Amygdala1.39
- Brain - Cortex1.24
- Brain - Anterior cingulate cortex (BA24)1.17
- Brain - Frontal Cortex (BA9)0.88
- Brain - Cerebellum0.86
- Brain - Hippocampus0.75
- Brain - Cerebellar Hemisphere0.55
- Pituitary0.05
- Nerve - Tibial0.04
- Testis0.03
- Fallopian Tube0.01
- Skin - Sun Exposed (Lower leg)0.01
- Cervix - Endocervix0.01
- Small Intestine - Terminal Ileum0
- Heart - Atrial Appendage0
- Adrenal Gland0
- Minor Salivary Gland0
And 29 more, listed on the interactive page.
- GO:0015732
- GO:0015742
- GO:0055085
- GO:0097254
- GO:0005886
- GO:0009925
- GO:0016323
- GO:0070062
- GO:0005452
- GO:0005515
- GO:0015132
- GO:0015139
- GO:0015297
- GO:0022857
- GO:0042910
Decrease, Population growth rate
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Biological samples
- proximal tubule
Evidence sourceIncreased Mortality
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Biological samples
- proximal tubule
Evidence source
Related records
Trials (61)
- 10-Propargyl-10-Deazaaminopterin Plus Probenecid in Treating Patients With Advanced Solid Tumors
- A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021)
- A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.
- A Phase 1 Study to Evaluate the Effect of the Organic Anion Transporter Inhibitor Probenecid on the Pharmacokinetics of JNJ-64041575 in Healthy Adults
- A Relative Bioavailability Study With a Novel PanCytoVir™ Oral Suspension (100 mg/ml)
- A Study in Healthy People to Test How 2 Different Formulations of BI 690517 Are Taken up in the Body and How Probenecid Influences the Amount of BI 690517 in the Blood
- A Study of Baricitinib and Probenecid in Healthy Participants
- A Study of Cidofovir in HIV-Infected Children With Cytomegalovirus (CMV) Disease
- A Study to Assess Pharmacokinetics of PF-04965842 and Its Metabolites and Effect of Probenecid in Healthy Participants
- A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants
- A Study to Assess the Effects of Multiple-Dose Probenecid on the Multiple-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers
- A Study to Evaluate the Drug-drug Interactions (DDIs) of DBPR108 With Warfarin Sodium, Digoxin, Probenecid in Healthy Subjects
- A Study to Evaluate the Efficacy of PanCytoVir™ for the Treatment of Non-Hospitalized Patients With COVID-19 Infection
- A Study to Evaluate the Use of Cidofovir (an Experimental Drug) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in AIDS Patients
- A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060
- A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects
- Addition of Probenecid to Penicillin-V Therapy
- An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS
- Assessment of a New "Boosting" Strategy for HIV Pre-exposure Prophylaxis in Healthy Volunteers
- AV-101 Alone and in Combination With Probenecid in Healthy Subjects
Drugs (2)
- Pratosartan Solute carrier family 22 member 6 inhibitor
- Probenecid Solute carrier family 22 member 6 inhibitor